ClinicalTrials.gg
RecruitingNCT07876440Updated Nov 18, 2026

A Clinical Study of HH-1270 in Healthy Chinese Subjects

A Phase 1 interventional study of HH-1270 and placebo in Chronic HDV Infection, sponsored by Huahui Health. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.

Read the detailed description

SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.

MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.

02

Conditions studied

  • Chronic HDV Infection
03

In context

Lead sponsor

Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
  • Weight: male ≥50.0 kg, female ≥45.0 kg, and (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
  • Results of vital signs, physical examination, laboratory tests, and 12-lead (ECG) at screening are normal or abnormal without clinical significance.
  • Participants must agree to take adequate and effective measures.
  • Participants understand and comply with the study procedures, voluntarily participate, and sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Individuals with severe systemic diseases, infectious diseases, or mental disorders.
  • (ECG) abnormalities.
  • History of clinically significant drug allergy or atopic allergic diseases.
  • Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
  • Positive results for (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
  • History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
  • Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
  • Blood donation ≥400 mL within 3 months before screening.
  • Participation in another interventional clinical trial within 3 months before screening.
  • Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
  • Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
  • Known or suspected history of allergy to any component of HH-1270 tablets or their .
  • Inability to accept standardized diet management at the study center.
  • Participants who are breastfeeding or have a positive pregnancy test before the first dose.
  • Participants deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    HH-1270 group

    SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

    Drug: HH-1270

  • Placebo comparator
    Placebo group

    SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

    Drug: placebo

Interventions

  • DrugHH-1270

    SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

  • Drugplacebo

    SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: up to 15/21 days in SAD/MAD

  2. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0.

    Time frame: up to 14/21 days in SAD/MAD

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  2. Maximum Plasma Concentration (Cmax)

    Cmax of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  3. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  4. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  5. Apparent Plasma Clearance (CL/F)

    CL/F of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  6. Apparent volume of distribution(Vd/F)

    Vd/F of HH-1270 in plasma

    Time frame: up to 8/14 days in SAD/MAD

  7. To evaluate the TBA level

    TBA level for each collection point

    Time frame: up to 15/21 days in SAD/MAD

  8. To evaluate the CP-1 level

    CP-1 level for each collection point

    Time frame: up to 15/21 days in SAD/MAD

Other outcomes

  1. To evaluate QTc change

    QTc values in each collection point

    Time frame: up to 8 days in SAD

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Feb 5, 2027
CompletionEst.
Jul 6, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
Peking University Third Hospital is now Recruiting
Nov 18, 2026
Registered
First appeared on the registry
Oct 15, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Peking University Third Hospital is now Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07876440
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 19, 2026
Primary completion
Feb 5, 2027 (estimated)
Completion
Jul 6, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Xiyu Zhang
Contact
zhangxiyu@hhhbio.com
18701650516

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion